Quantcast

Latest Anti-neutrophil cytoplasmic antibody Stories

2011-10-28 12:03:12

Substance in the blood blocks repair and contributes to kidney failure     Patients with an autoimmune disease called anti-neutrophil cytoplasmic antibody-associated vasculitis produce antibodies that damage blood vessels in the kidneys.     Patients with the disease harbor elevated blood levels of the protein Flt1, which hinders blood vessel repair.     Inhibiting Flt1 may help prevent kidney failure in the 1:50,000 patients around the world...

2010-11-10 08:00:00

MOUNTAIN VIEW, Calif., Nov. 10, 2010 /PRNewswire/ -- ChemoCentryx, Inc., today announced favorable Phase I results for CCX168 at the Annual American College of Rheumatology Meeting (ACR). CCX168, the Company's orally-active small molecule antagonist, is designed to target the receptor for the pro-inflammatory protein known as 'complement 5a' (C5a), a so-called anaphylatoxin that drives inflammatory responses associated with autoimmune diseases such as vasculitis, aged-related macular...

2010-07-15 13:55:37

Investigators have made a major advance in treating people with a severe form of vasculitis, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare but devastating disease of blood vessels. In a six-month study, a new treatment strategy provided the same benefits as the current standard of care used for more than 40 years but required less frequent treatments. Early results also suggest that patients with disease relapses"”typically recurrences of fever, fatigue,...

2010-07-15 13:30:56

Researchers have reported that Rituximab, a drug that is FDA approved to treat B cell lymphoma and rheumatoid arthritis, can also treat severe vasculitis as well as the current standard therapy. Infertility and the development of cancers have been associated with the traditionally used medication, cyclophosphamide, and the risk of these complications is expected to be much lower with Rituximab. The news will be published in the July 14 issue of the New England Journal of Medicine. "The reason...

2010-07-15 13:25:10

 Two UNC School of Medicine faculty authored an editorial in the July 15, 2010 New England Journal of Medicine commenting on results from two clinical trials using the drug Rituximab to treat small-vessel vasculitis, a rare autoimmune disease. The trials took place in the United States "“ Rituximab in ANCA-Associated Vasculitis (RAVE) -- and in Europe -- Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis (RITUXIVAS). Both trials showed that rituximab was...

2008-08-21 09:00:22

SAN DIEGO, Aug. 21 /PRNewswire/ -- Prometheus Laboratories Inc. announced the issuance of U.S. Patent No. 7,361,733, "Compositions and Methods for the Therapy and Diagnosis of Inflammatory Bowel Disease" which protects a flagellin peptide useful in the detection of antibodies to the flagellin CBir1, or anti-CBir1, for determining the presence of inflammatory bowel disease (IBD). This proprietary technology is used in the Company's PROMETHEUS(R) IBD Serology 7 test and its recently launched...

2004-11-27 03:00:10

Abstract Wegener's granulomatosis is a multisystemic disease characterized by foci of necrotizing vasculitis and granuloma formation. Subglottic stenosis may occur either as a presenting feature or a late-stage manifestation of the disease, but will occur in approximately 10-20 per cent of cases. We present a series of seven cases of Wegener's granulomatosis with subglottic stenosis and discuss our management of this condition. Where there is active disease, tracheostomy is the first-...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related